CClinicalTrials.gg
TerminatedNCT03517553Updated Jan 8, 2025Results posted

Effects of Exercise by Neuromuscular Stimulation in Dialysis Patients

An interventional study of EMS users in ESRD in Dialysis, sponsored by University of Iowa. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by University of Iowa · Not applicable, Interventional, and Treatment

Why this study was terminated
Study subjects that were enrolled all completed all visits. PI is currently unable to work on analyzing results

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Jul 2013, registered Feb 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The investigators propose a pilot feasibility study to determine if exercise delivered by passive electrical muscle stimulation (EMS) in patients with end stage renal disease (ESRD) on hemodialysis improves physical fitness and insulin resistance, outcome markers associated with morbidity and mortality in this population.

Read the detailed description

Subjects who enroll and meet the inclusion and none of the exclusion criteria will first undergo baseline testing including recording of demographic, medical, dialysis and exercise history, taking surveys to assess quality of life and overall mood, measurement of vital signs and anthropomorphic measurements (height, weight, thigh circumference), have blood collected to assess insulin resistance and cytokine levels, measurement of distance walked in 6 minutes and testing of thigh muscle strength.

Subjects will then undergo a 1 month observation period to monitor and optimize their dialysis treatment.

After 1 month the subjects will undergo a repeat assessment of all the baseline testing. They will also undergo a standardized exercise stress test and measurement of body fat and lean body mass with a dual-energy x-ray absorptiometry (DXA) scan.

Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator ("EMPI 300PV" or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.

At 2 and 4 months the subjects will undergo again have repeat assessment of the baseline testing as well as undergoing the standardized exercise stress test and a DXA scan.

At 4 months the subjects will all stop the passive exercise training and then will be followed up 1 month later to repeat assessment of all the baseline testing but will not undergoing the standardized exercise stress test and a DXA scan.

For subjects who agree the investigators will also perform a muscle biopsy under local anesthesia before and 4 hours after the first exercise training session and again at 2 and 4 months. This is used to measure messenger RNA response (gene expression testing) to tell what genes are activated during training.

The efficacy of the exercise training will be assessed by change in aerobic capacity measured by maximal oxygen consumption (peak VO2) and quadriceps muscle strength measured

The primary outcome measure will be whether exercise training improves measures of insulin resistance The investigators will also assess whether there is improvement in other inflammatory and oxidative stress cytokines in the blood stream and whether the training improved their physical performance or overall quality of life.

The total duration of the study for any patient is expected to be 6 months.

02

Conditions studied

  • Dialysis

Keywords

  • electrical muscle stimulation
03

In context

Lead sponsor

University of Iowa is the lead sponsor of 276 studies on the registry; 35 are open to participants now.

Of its 44 completed or terminated interventional studies of FDA-regulated products, 39 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Able to provide informed consent
  2. Currently on maintenance hemodialysis for end stage renal disease and expected to stay in the participating dialysis unit for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  1. The presence of a cardiac pacemaker or presence of any other implanted electrical stimulation device
  2. Uncontrolled hypertension as defined by a systolic BP >170 mmHg
  3. Current presence of unstable angina
  4. A heart attack (myocardial infarction) within the last month
  5. Expected survival less than 6 months
  6. Unsuitable for participation based on physician assessment
  7. Pregnancy
  8. Unwilling or unable to give informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    EMS users in ESRD

    Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.

    Device: EMS users in ESRD

Interventions

  • DeviceEMS users in ESRD

    use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis

06

What researchers measure

Primary outcomes

  1. Quadriceps Muscle Strength Measured by a Belt-stabilized Portable Dynamometer

    Muscle strength was measured using a belt-stabilized hand held dynamometer (BSHHD) using a validated technique. Briefly, isometric knee extension strength (torque) was measured with patients seated on an elevated chair and their knees bent at about 90o of flexion (i.e., the legs hanging vertical). Patients are stabilized to the chair with straps around proximal thighs and waist. A dynamometer-stabilizing belt is passed around a bar secured behind the back legs of the chair and over a calibrated hand-held dynamometer that was placed against the anterior leg of the patient just proximal to the malleoli. The patient is asked to perform three leg extensions with the leg separated by 30 seconds of rest. The first effort is sub-maximal to get the patient accustom to the procedure. Then two full strength efforts are performed and used for calculation of average peak force (newtons, N) generated. The test is performed sequentially on both legs at each measurement session.

    Time frame: Baseline, Start EMS, 2 months and 4 months of EMS training, and 1 month post exercise

Secondary outcomes

  1. Leg Composition by Dual Energy X-ray Absorptiometry (DXA).

    Advanced body composition analysis will be performed by DXA scan to measure regional fat and lean mass before starting EMS training and again after 2 and 4 months of EMS training. Specific areas of interest will be in determining whether EMS training produces the expected changes in thigh fat and muscle mass. The test is performed in the CRU at the University of Iowa using a Discovery A DXA scanner with the latest software version package (Hologic Inc., Bedford, MA). The advanced body composition analysis software package measures total regional body composition (cm2) using a validated technique that produces comparable results to a CT scan with less cost and radiation exposure.The total radiation dose is less than one tenth that of a standard CXR and equivalent to one-day exposure to natural background radiation. Patients will be asked to report to the CRU dressed metal-free (no zippers, jewelry, piercings, underwire bra, etc.). Each study will take approximately 30 minutes.

    Time frame: Baseline, 2 and 4 months of EMS training

07

Results

Posted Jan 8, 2025

Participant flow

Recruitment from July 29, 2013 to March 25, 2014. All patients were from the outpatient dialysis program at the University of Iowa.

Participant flow — Overall Study
MilestoneEMS Users in ESRD
Started7
Completed5
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryQuadriceps Muscle Strength Measured by a Belt-stabilized Portable Dynamometer

Muscle strength was measured using a belt-stabilized hand held dynamometer (BSHHD) using a validated technique. Briefly, isometric knee extension strength (torque) was measured with patients seated on an elevated chair and their knees bent at about 90o of flexion (i.e., the legs hanging vertical). Patients are stabilized to the chair with straps around proximal thighs and waist. A dynamometer-stabilizing belt is passed around a bar secured behind the back legs of the chair and over a calibrated hand-held dynamometer that was placed against the anterior leg of the patient just proximal to the malleoli. The patient is asked to perform three leg extensions with the leg separated by 30 seconds of rest. The first effort is sub-maximal to get the patient accustom to the procedure. Then two full strength efforts are performed and used for calculation of average peak force (newtons, N) generated. The test is performed sequentially on both legs at each measurement session.

Time frame:
Baseline, Start EMS, 2 months and 4 months of EMS training, and 1 month post exercise
Reported as:
Mean · Force (Newtons)
Quadriceps Muscle Strength Measured by a Belt-stabilized Portable Dynamometer
Force (Newtons)Right Quadriceps Strength.Left Quadriceps Strength
Baseline221.2 ± 81.8227.4 ± 65.6
Start EMS222.4 ± 80.4213.5 ± 81.7
2 months EMS Training219.2 ± 73.6213.9 ± 50.4
4 months EMS Training235.8 ± 59.9204.7 ± 80.3
1 month Post-EMS training226.4 ± 63.8151.9 ± 88.8
Statistical analysis
  • Right Quadriceps Strength. vs Left Quadriceps Strength · Kruskal-Wallis · p = 0.999 (Threshold for statistical significance is P\<0.05)
  • Left Quadriceps Strength · Kruskal-Wallis · p = 0.768
SecondaryLeg Composition by Dual Energy X-ray Absorptiometry (DXA).

Advanced body composition analysis will be performed by DXA scan to measure regional fat and lean mass before starting EMS training and again after 2 and 4 months of EMS training. Specific areas of interest will be in determining whether EMS training produces the expected changes in thigh fat and muscle mass. The test is performed in the CRU at the University of Iowa using a Discovery A DXA scanner with the latest software version package (Hologic Inc., Bedford, MA). The advanced body composition analysis software package measures total regional body composition (cm2) using a validated technique that produces comparable results to a CT scan with less cost and radiation exposure.The total radiation dose is less than one tenth that of a standard CXR and equivalent to one-day exposure to natural background radiation. Patients will be asked to report to the CRU dressed metal-free (no zippers, jewelry, piercings, underwire bra, etc.). Each study will take approximately 30 minutes.

Time frame:
Baseline, 2 and 4 months of EMS training
Reported as:
Mean · cm squared
Leg Composition by Dual Energy X-ray Absorptiometry (DXA).
cm squaredRight Total Thigh MassRight Thigh Fat MassRight Thigh Lean MassLeft Total Thigh MassLeft Thigh Fat MassLeft Thigh Lean Mass
Baseline12458 ± 15014861 ± 11787369 ± 48112492 ± 14984946 ± 11777301 ± 471
2 Months EMS Training12484 ± 14134835 ± 10427417 ± 54212842 ± 16605109 ± 11647489 ± 607
4 Months EMS Training12540 ± 15534912 ± 11187392 ± 55012831 ± 17065126 ± 12207453 ± 582
Statistical analysis
  • Right Total Thigh Mass · Kruskal-Wallis · p = 0.869
  • Right Thigh Fat Mass · Kruskal-Wallis · p = 0.813
  • Right Thigh Lean Mass · Kruskal-Wallis · p = 0.978
  • Left Total Thigh Mass · Kruskal-Wallis · p = 0.731
  • Left Thigh Fat Mass · Kruskal-Wallis · p = 0.703
  • Left Thigh Lean Mass · Kruskal-Wallis · p = 0.909

Adverse events

Collected over Adverse events were collected for 24 weeks on each patient. Adverse events were collected at the time of each study visit up to the last study visit which was 4 weeks after stopping the EMS training. Adverse events were also collected at any time we became aware of an adverse event during the period of the 24 weeks the patient was enrolled in the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EMS Training Group0/7 (0%)1/7 (14.3%)0/7 (0%)
Most frequent serious events
Most frequent serious events
EventEMS Training Group
Transient ischemic attackNervous system disorders1/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)EMS Users
Mean68.9 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)EMS Users
Female3
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EMS Users
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EMS Users
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)EMS Users
United States7
History diabetes
History diabetes(Participants)EMS Users
Count of participants6
08

Study locations

1 site
  • University of Iowa
    Iowa City, Iowa 52242, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 11, 2013

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03517553
Lead sponsor
University of Iowa
Responsible party
Sponsor
First posted
May 7, 2018
Start date
Jul 29, 2013
Primary completion
Nov 12, 2014
Completion
Nov 12, 2014
Results posted
Jan 8, 2025
Last update
Jan 8, 2025

Study contacts

Bradley S Dixon, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion